アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
A synthetic peptide corresponding to residues in the Calmodulin binding region of human EEF2K was used as immunogen.
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
Our Abpromise guarantee covers the use of ab46787 in the following tested applications.
|WB||1/50000. Detects a band of approximately 95 kDa (predicted molecular weight: 82 kDa).|
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: EEF2K knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: Jurkat cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab46787 observed at 95 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab46787 was shown to specifically react with EEF2K when EEF2K knockout samples were used. Wild-type and EEF2K knockout samples were subjected to SDS-PAGE. ab46787 and ab8245 (loading control to GAPDH) were diluted at 1/50 000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
ab46787 has not yet been referenced specifically in any publications.